Bellicum Announced Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
Bellicum Pharmaceuticals, Inc.
Warren Buffett-Backed Paytm Stock Jumps 7% On Possible Buyback Plan
Shares of One 97 Communications Ltd., which operates Paytm, India’s largest digital payments provider, soared over 7% in intraday trade on Friday after the co
EXCLUSIVE: Benzinga Announces 2022 Global Fintech Award Winners — See Who’s Moving The Industry Forward Here
Leading financial media outlet Benzinga hosted its annual Global Fintech Deal Day & Awards Thursday at Pier Sixty in New York City.
Here's a look at the annual event and the 2022 award winners.
EXCLUSIVE: Crypto Contagion Infects Fintech — But It’s Apples And Oranges, Symbiont CEO Says
Blockchain, the technology that underpins cryptocurrencies such as Bitcoin (CRYPTO: BTC), can propel a traditional financial services firm into the next frontier of fintech.
EXCLUSIVE: Wall Street Still Likes Crypto Even After The FTX Collapse: Here’s Why
Throughout 2022, the cryptocurrency sector sent out shockwaves that hit investors and those interested in entering into the market — particularly Wall Street and fintech — with the most recent collapse of FTX hurting the development of trust between Wall Street, fintech and cryptocurrencies.
EXCLUSIVE: Why The Largest Custodian Bank In The World Sees Opportunity In Tokenization, Not Cryptocurrencies
State Street (NYSE: STT) has ramped up its focus on digital assets and tokenization as it sees significant opportunity in the space.
EXCLUSIVE: FTX Collapse Brings Crypto Regulation To The Forefront — Here’s What 4 Experts Say The Rules Should Look Like
The lack of clarity and regulation around cryptocurrency was most recently underscored by the spectacular collapse of FTX. The details of FTX's failure are still being uncovered, and the exchange's bankrupcy came on the heels of several other nascent crypto companies that folded.
Oncolytics Biotech’s Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating The Anti-Cancer Activity Of Pelareorep-Paclitaxel Combination Therapy In HR+/HER2- Metastatic Breast Cancer At SABCS
Thirteen of fourteen (93%) evaluable patients achieved disease control, with twelve (86%) showing tumor shrinkage
SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /CNW/ -- Oncolytics
INmune Bio Data At ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence Of Cancer Killing Memory Like NK Cells In Patients With AML/MDS Following Treatment With INKmune
INmune Bio, Inc. (NASDAQ:INMB) ("INMB" or "the Company"), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system